• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Precision for Medicine acquires Precision Health Economics

Precision for Medicine acquires Precision Health Economics

April 17, 2015
CenterWatch Staff

Precision for Medicine, a Bethesda, Md.- based specialized services company supporting next-generation approaches to drug development and commercialization, has acquired Precision Health Economics (PHE), a health economics consultancy and analytics firm. PHE leverages the experience of policy analysts, economists, clinicians and academics to advance research on the most complex healthcare questions. Life sciences companies and policymakers worldwide turn to PHE to shape strategy, inform key healthcare decisions, and produce effective changes in policy through innovative research.

PHE, headquartered in Los Angeles, was founded by Drs. Dana Goldman, Darius Lakdawalla and Tomas Philipson, professors at the University of Southern California and the University of Chicago. PHE's network of academic experts includes numerous nationally and globally recognized scholars in health economics, medicine and health policy. The team also includes former leaders at the Centers for Medicare and Medicaid Services, the FDA, the Department of the Treasury, the Congressional Budget Office and the President's Council of Economic Advisers.

Ethan Leder, chairman, Precision for Medicine, said, "Adding PHE's differentiated capabilities fortifies our approach to helping life sciences companies deliver more effective treatments to patients in the era of precision medicine by integrating research, analytics, science and communications. The PHE management team will remain in place and will continue to focus on their customers in the pharmaceutical and life sciences markets."

"In the age of personalized medicine, it's vitally important to understand not only how value derives from tailored treatment, but also how to navigate the data, analytics and policy challenges associated with precision medicine," said Goldman of PHE.

"This acquisition provides us access to a pool of talent, knowledge and expertise in the healthcare payer marketplace that will provide our clients deeper insights into the scope and scale of economic evidence required to shape future policy decisions," said Glenn Bilawsky, who will become president of PHE.

This acquisition will expand the existing health economics and outcomes research (HEOR) capabilities of Precision for Value, a business unit of Precision for Medicine. Precision for Value helps pharmaceutical and life sciences companies demonstrate and communicate the value of innovative medications. The company's clients achieve an in-depth understanding of the specific drivers and barriers that impact market access. The acquisition extends the leadership in HEOR with a focus on innovative approaches to evidence generation.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing